Kidney Cancer VL

Treatment Strategies in Kidney Cancer and the Results of CARMENA - Toni Choueiri

Details
(Length of Discussion: 9 min) Alicia Morgans and Toni Choueiri provide a review of the historical background evolving from the era of targeted therapy to the current landscape in kidney cancer incorporating the surprising results from the CARMENA trial. Biographies: Toni K. Choueiri, MD, Jerome and Nancy Kohlberg Professor, Medicine, Harvard Medical School, Attending Physician, Solid Tumor Oncolog...

CABOSUN Trial Plus an In-depth Discussion of Kidney Cancer Treatments - Toni Choueiri

Details
(Length of Discussion: 22 min) Alicia Morgans and Toni Choueiri engage in a discussion on the treatment options available for mRCC. Toni presents a thorough review of the CABOSUN results, further addressing the process of choosing the right first-line therapy for these patients with intermediate, and poor risk disease. His extensive work in research provides an optimistic vision of having a biomar...

CARMENA: Practice Changing Strategies for Kidney Cancer

Details
(Length of Discussion: 6 min) Charles Ryan and Dan George reflect on the dramatic changes clinicians have seen over the last 12 years in treating kidney cancer. Dan reviews the highlights of the CARMENA trial and the impact that the results have made to treatment strategies for patients, stressing the value of collaborative care and patient selection. Biographies: Daniel George, MD Charles J. Ryan...

Over-treatment of Renal Tumors: The Turtle in the Room - Robert G. Uzzo

Details
(Length of discussion - 11 minutes) Kidney cancer, like all cancers, has a spectrum of risk. There are groups of patients with incidentally detected asymptomatic, small renal masses that act relatively indolent and are often over-diagnosed and over-treated in some patients. The issue is defining who they are when they should or should not be treated. Related Content: Watch: Adjuvant Therapies for...

Adjuvant Therapies for Renal Cell Carcinoma - Robert Uzzo

Details
(Length of discussion - 21 minutes) David Crawford discusses adjuvant therapy in kidney cancer with Robert Uzzo, and the fact that although there have been three decades of trials, there is still no approved therapies to treat the disease. However, Dr. Uzzo points to the S-TRAC trial as a step forward in that research space. Related Content: Watch: Over-treatment of Renal Tumors: The Turtle in the...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe